US Broker Ratings

Xencor, Inc. (XNCR)

⚠️ No article content returned.

..

AxoGen, Inc. (AXGN) Investor Outlook: Strong Buy Ratings Highlight a Potential 101.54% Upside

For investors eyeing opportunities in the healthcare sector, AxoGen, Inc. (NASDAQ: AXGN) presents an intriguing proposition with its focus on pioneering technologies for peripheral nerve regeneration and repair. Headquartered in..

Keros Therapeutics, Inc. (KROS) Stock Analysis: A Biotech Gem with Over 100% Potential Upside

Keros Therapeutics, Inc. (NASDAQ: KROS), a promising player in the biotechnology sector, has been making waves with its innovative approach to addressing complex medical conditions. With a focus on novel..

Oruka Therapeutics, Inc. (ORKA) Stock Analysis: Exploring a Potential 180% Upside in Biotech

Oruka Therapeutics, Inc. (ORKA) is carving a niche for itself within the biotechnology sector, focusing on innovative treatments for psoriasis and other inflammatory conditions. As a clinical-stage biopharmaceutical company based..

Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: A 65% Upside Potential in the Biotech Arena

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC), a cutting-edge player in the biotechnology sector, is currently captivating investors with its promising pipeline and notable upside potential. With a market capitalization of $1.02..

ATAI Life Sciences N.V. (ATAI) Stock Analysis: Unlocking a 229.67% Potential Upside in Biotech Innovation

ATAI Life Sciences N.V. (NASDAQ: ATAI) is capturing the attention of investors with its pioneering approach to mental health treatments and a staggering potential upside of 229.67%. As a clinical-stage..

Sonida Senior Living, Inc. (SNDA): Investor Outlook on a Healthcare Growth Story with 31% Revenue Surge

Sonida Senior Living, Inc. (SNDA), a prominent player in the healthcare sector under the Medical Care Facilities industry, is drawing attention with a remarkable 31% revenue growth. Based in Dallas,..

Emergent BioSolutions Inc. (EBS) Stock Analysis: Navigating a Challenging Landscape with an 84% Potential Upside

Emergent BioSolutions Inc. (NYSE: EBS), a prominent player in the healthcare sector, specializes in drug manufacturing with a focus on specialty and generic solutions. The company’s portfolio is diverse, offering..

Verastem, Inc. (VSTM) Stock Analysis: Exploring the 221% Potential Upside in Biotech Investment

Verastem, Inc. (NASDAQ: VSTM) presents an intriguing opportunity for investors with its significant potential upside of over 221%, according to analyst ratings. As a biopharmaceutical company at the forefront of..

Fulgent Genetics, Inc. (FLGT) Stock Analysis: Navigating Growth Potential with a 15.94% Upside

Fulgent Genetics, Inc. (NASDAQ: FLGT) stands at a crossroads with its intriguing blend of clinical diagnostic and therapeutic development solutions. With a market capitalization of $595.17 million, this healthcare diagnostics..

Verve Therapeutics (VERV) Stock Analysis: Unveiling a 36.6% Potential Upside with Cutting-Edge Gene Editing Innovations

Verve Therapeutics, Inc. (NASDAQ: VERV) is capturing investor attention in the biotechnology sector with its promising gene editing medicines aimed at combating cardiovascular diseases. Operating from its base in Boston,..

Definitive Healthcare Corp. (DH) Stock Analysis: Navigating Through Headwinds with Strategic Insights

Definitive Healthcare Corp. (NASDAQ: DH) stands at a crucial juncture as it navigates the dynamic landscape of the healthcare information services industry. With a market capitalization of $450.84 million, the..

Prothena Corporation (PRTA) Stock Analysis: Exploring a Potential 269.65% Upside in Biotech

Prothena Corporation plc (NASDAQ: PRTA), a promising player in the biotechnology sector, is capturing investor attention with its remarkable 269.65% potential upside. Headquartered in Dublin, Ireland, Prothena is dedicated to..

Day One Biopharmaceuticals, Inc (DAWN) Stock Analysis: Exploring a Potential 289% Upside

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) is capturing the attention of investors with its compelling growth potential in the biotechnology sector. With a market capitalization of $748.58 million, this healthcare..

Abivax SA (ABVX) Stock Analysis: Unveiling a 341% Upside Potential

For investors with a penchant for healthcare opportunities, Abivax SA (ABVX) presents an intriguing prospect in the biotechnology sector. Based in France, Abivax is a clinical-stage biotech company that focuses..

LifeMD, Inc. (LFMD) Stock Analysis: Telehealth Innovator with a Promising 48.8% Revenue Growth

LifeMD, Inc. (NASDAQ: LFMD) is emerging as a significant player in the rapidly evolving healthcare sector, specifically within the health information services industry. With a market capitalization of $551.86 million,..

COMPASS Pathways Plc (CMPS): Analyst Ratings Suggest 327% Upside Potential in Mental Health Breakthroughs

For investors seeking opportunities in the healthcare sector, COMPASS Pathways Plc (NASDAQ: CMPS) presents an intriguing case. As a pioneering biotechnology firm focused on mental health, COMPASS Pathways is capturing..

Nuvation Bio Inc. (NUVB) Stock Analysis: Exploring a 210% Potential Upside in the Biotech Sector

Nuvation Bio Inc. (NASDAQ: NUVB) stands out in the competitive biotech sector with a compelling story for investors seeking high-growth potential. As a clinical-stage biopharmaceutical company, Nuvation Bio focuses on..

Inventiva S.A. – American Depos (IVA) Stock Analysis: Unveiling a 222% Potential Upside in the Biotechnology Sector

Inventiva S.A. – American Depos (IVA) is a promising player in the biotechnology industry, attracting attention from investors seeking substantial growth in their portfolios. Headquartered in Daix, France, Inventiva is..

Tourmaline Bio, Inc. (TRML) Investor Outlook: Exploring a 220% Potential Upside in the Biotech Sector

Tourmaline Bio, Inc. (NASDAQ: TRML), a promising player in the biotechnology sector, is catching the attention of investors with its substantial potential upside. With a market capitalization of $449.31 million,..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds